CL Educate Limited
CL Educate Limited (CLEDUCATE.BO) Stock Competitors & Peer Comparison
See (CLEDUCATE.BO) competitors and their performances in Stock Market.
Peer Comparison Table: Education & Training Services Industry
Detailed financial metrics including price, market cap, P/E ratio, and more.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| CLEDUCATE.BO | ₹46.47 | -0.09% | 2.5B | -11.25 | -₹4.09 | N/A |
| PWL.BO | ₹111.95 | +0.86% | 320.4B | -131.82 | -₹0.85 | N/A |
| PWL.NS | ₹111.99 | +0.90% | 320.4B | -133.37 | -₹0.84 | N/A |
| CRIZAC.BO | ₹227.50 | +1.49% | 41.9B | 19.85 | ₹12.06 | +3.35% |
| CRIZAC.NS | ₹227.33 | +1.49% | 41.8B | 21.75 | ₹10.98 | +3.35% |
| NIITMTS.BO | ₹214.25 | -2.01% | 29.8B | 12.27 | ₹17.67 | +1.39% |
| NIITMTS.NS | ₹214.00 | -2.39% | 29.8B | 12.24 | ₹17.67 | +1.39% |
| VERANDA.BO | ₹232.45 | -2.23% | 22.9B | 24.67 | ₹9.64 | N/A |
| VERANDA.NS | ₹233.37 | -1.88% | 22.8B | 24.56 | ₹9.66 | N/A |
| NIITLTD.BO | ₹67.95 | -1.45% | 9.3B | 40.67 | ₹1.67 | +1.47% |
Stock Comparison
CLEDUCATE.BO vs PWL.BO Comparison May 2026
CLEDUCATE.BO plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CLEDUCATE.BO stands at 2.5B. In comparison, PWL.BO has a market cap of 320.4B. Regarding current trading prices, CLEDUCATE.BO is priced at ₹46.47, while PWL.BO trades at ₹111.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CLEDUCATE.BO currently has a P/E ratio of -11.25, whereas PWL.BO's P/E ratio is -131.82. In terms of profitability, CLEDUCATE.BO's ROE is -0.10%, compared to PWL.BO's ROE of -0.14%. Regarding short-term risk, CLEDUCATE.BO is more volatile compared to PWL.BO. This indicates potentially higher risk in terms of short-term price fluctuations for CLEDUCATE.BO.Check PWL.BO's competition here
CLEDUCATE.BO vs PWL.NS Comparison May 2026
CLEDUCATE.BO plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CLEDUCATE.BO stands at 2.5B. In comparison, PWL.NS has a market cap of 320.4B. Regarding current trading prices, CLEDUCATE.BO is priced at ₹46.47, while PWL.NS trades at ₹111.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CLEDUCATE.BO currently has a P/E ratio of -11.25, whereas PWL.NS's P/E ratio is -133.37. In terms of profitability, CLEDUCATE.BO's ROE is -0.10%, compared to PWL.NS's ROE of -0.14%. Regarding short-term risk, CLEDUCATE.BO is more volatile compared to PWL.NS. This indicates potentially higher risk in terms of short-term price fluctuations for CLEDUCATE.BO.Check PWL.NS's competition here
CLEDUCATE.BO vs CRIZAC.BO Comparison May 2026
CLEDUCATE.BO plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CLEDUCATE.BO stands at 2.5B. In comparison, CRIZAC.BO has a market cap of 41.9B. Regarding current trading prices, CLEDUCATE.BO is priced at ₹46.47, while CRIZAC.BO trades at ₹227.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CLEDUCATE.BO currently has a P/E ratio of -11.25, whereas CRIZAC.BO's P/E ratio is 19.85. In terms of profitability, CLEDUCATE.BO's ROE is -0.10%, compared to CRIZAC.BO's ROE of +0.35%. Regarding short-term risk, CLEDUCATE.BO is less volatile compared to CRIZAC.BO. This indicates potentially lower risk in terms of short-term price fluctuations for CLEDUCATE.BO.Check CRIZAC.BO's competition here
CLEDUCATE.BO vs CRIZAC.NS Comparison May 2026
CLEDUCATE.BO plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CLEDUCATE.BO stands at 2.5B. In comparison, CRIZAC.NS has a market cap of 41.8B. Regarding current trading prices, CLEDUCATE.BO is priced at ₹46.47, while CRIZAC.NS trades at ₹227.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CLEDUCATE.BO currently has a P/E ratio of -11.25, whereas CRIZAC.NS's P/E ratio is 21.75. In terms of profitability, CLEDUCATE.BO's ROE is -0.10%, compared to CRIZAC.NS's ROE of +0.35%. Regarding short-term risk, CLEDUCATE.BO is less volatile compared to CRIZAC.NS. This indicates potentially lower risk in terms of short-term price fluctuations for CLEDUCATE.BO.Check CRIZAC.NS's competition here
CLEDUCATE.BO vs NIITMTS.BO Comparison May 2026
CLEDUCATE.BO plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CLEDUCATE.BO stands at 2.5B. In comparison, NIITMTS.BO has a market cap of 29.8B. Regarding current trading prices, CLEDUCATE.BO is priced at ₹46.47, while NIITMTS.BO trades at ₹214.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CLEDUCATE.BO currently has a P/E ratio of -11.25, whereas NIITMTS.BO's P/E ratio is 12.27. In terms of profitability, CLEDUCATE.BO's ROE is -0.10%, compared to NIITMTS.BO's ROE of +0.19%. Regarding short-term risk, CLEDUCATE.BO is less volatile compared to NIITMTS.BO. This indicates potentially lower risk in terms of short-term price fluctuations for CLEDUCATE.BO.Check NIITMTS.BO's competition here
CLEDUCATE.BO vs NIITMTS.NS Comparison May 2026
CLEDUCATE.BO plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CLEDUCATE.BO stands at 2.5B. In comparison, NIITMTS.NS has a market cap of 29.8B. Regarding current trading prices, CLEDUCATE.BO is priced at ₹46.47, while NIITMTS.NS trades at ₹214.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CLEDUCATE.BO currently has a P/E ratio of -11.25, whereas NIITMTS.NS's P/E ratio is 12.24. In terms of profitability, CLEDUCATE.BO's ROE is -0.10%, compared to NIITMTS.NS's ROE of +0.19%. Regarding short-term risk, CLEDUCATE.BO is more volatile compared to NIITMTS.NS. This indicates potentially higher risk in terms of short-term price fluctuations for CLEDUCATE.BO.Check NIITMTS.NS's competition here
CLEDUCATE.BO vs VERANDA.BO Comparison May 2026
CLEDUCATE.BO plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CLEDUCATE.BO stands at 2.5B. In comparison, VERANDA.BO has a market cap of 22.9B. Regarding current trading prices, CLEDUCATE.BO is priced at ₹46.47, while VERANDA.BO trades at ₹232.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CLEDUCATE.BO currently has a P/E ratio of -11.25, whereas VERANDA.BO's P/E ratio is 24.67. In terms of profitability, CLEDUCATE.BO's ROE is -0.10%, compared to VERANDA.BO's ROE of +0.25%. Regarding short-term risk, CLEDUCATE.BO is less volatile compared to VERANDA.BO. This indicates potentially lower risk in terms of short-term price fluctuations for CLEDUCATE.BO.Check VERANDA.BO's competition here
CLEDUCATE.BO vs VERANDA.NS Comparison May 2026
CLEDUCATE.BO plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CLEDUCATE.BO stands at 2.5B. In comparison, VERANDA.NS has a market cap of 22.8B. Regarding current trading prices, CLEDUCATE.BO is priced at ₹46.47, while VERANDA.NS trades at ₹233.37.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CLEDUCATE.BO currently has a P/E ratio of -11.25, whereas VERANDA.NS's P/E ratio is 24.56. In terms of profitability, CLEDUCATE.BO's ROE is -0.10%, compared to VERANDA.NS's ROE of +0.25%. Regarding short-term risk, CLEDUCATE.BO is less volatile compared to VERANDA.NS. This indicates potentially lower risk in terms of short-term price fluctuations for CLEDUCATE.BO.Check VERANDA.NS's competition here
CLEDUCATE.BO vs NIITLTD.BO Comparison May 2026
CLEDUCATE.BO plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CLEDUCATE.BO stands at 2.5B. In comparison, NIITLTD.BO has a market cap of 9.3B. Regarding current trading prices, CLEDUCATE.BO is priced at ₹46.47, while NIITLTD.BO trades at ₹67.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CLEDUCATE.BO currently has a P/E ratio of -11.25, whereas NIITLTD.BO's P/E ratio is 40.67. In terms of profitability, CLEDUCATE.BO's ROE is -0.10%, compared to NIITLTD.BO's ROE of +0.00%. Regarding short-term risk, CLEDUCATE.BO is more volatile compared to NIITLTD.BO. This indicates potentially higher risk in terms of short-term price fluctuations for CLEDUCATE.BO.Check NIITLTD.BO's competition here
CLEDUCATE.BO vs NIITLTD.NS Comparison May 2026
CLEDUCATE.BO plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CLEDUCATE.BO stands at 2.5B. In comparison, NIITLTD.NS has a market cap of 9.3B. Regarding current trading prices, CLEDUCATE.BO is priced at ₹46.47, while NIITLTD.NS trades at ₹68.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CLEDUCATE.BO currently has a P/E ratio of -11.25, whereas NIITLTD.NS's P/E ratio is 40.63. In terms of profitability, CLEDUCATE.BO's ROE is -0.10%, compared to NIITLTD.NS's ROE of +0.00%. Regarding short-term risk, CLEDUCATE.BO is more volatile compared to NIITLTD.NS. This indicates potentially higher risk in terms of short-term price fluctuations for CLEDUCATE.BO.Check NIITLTD.NS's competition here
CLEDUCATE.BO vs APTECHT.NS Comparison May 2026
CLEDUCATE.BO plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CLEDUCATE.BO stands at 2.5B. In comparison, APTECHT.NS has a market cap of 6.5B. Regarding current trading prices, CLEDUCATE.BO is priced at ₹46.47, while APTECHT.NS trades at ₹107.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CLEDUCATE.BO currently has a P/E ratio of -11.25, whereas APTECHT.NS's P/E ratio is 24.24. In terms of profitability, CLEDUCATE.BO's ROE is -0.10%, compared to APTECHT.NS's ROE of +0.10%. Regarding short-term risk, CLEDUCATE.BO is less volatile compared to APTECHT.NS. This indicates potentially lower risk in terms of short-term price fluctuations for CLEDUCATE.BO.Check APTECHT.NS's competition here
CLEDUCATE.BO vs APTECHT.BO Comparison May 2026
CLEDUCATE.BO plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CLEDUCATE.BO stands at 2.5B. In comparison, APTECHT.BO has a market cap of 6.5B. Regarding current trading prices, CLEDUCATE.BO is priced at ₹46.47, while APTECHT.BO trades at ₹107.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CLEDUCATE.BO currently has a P/E ratio of -11.25, whereas APTECHT.BO's P/E ratio is 20.83. In terms of profitability, CLEDUCATE.BO's ROE is -0.10%, compared to APTECHT.BO's ROE of +0.10%. Regarding short-term risk, CLEDUCATE.BO is less volatile compared to APTECHT.BO. This indicates potentially lower risk in terms of short-term price fluctuations for CLEDUCATE.BO.Check APTECHT.BO's competition here
CLEDUCATE.BO vs GLOBAL.NS Comparison May 2026
CLEDUCATE.BO plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CLEDUCATE.BO stands at 2.5B. In comparison, GLOBAL.NS has a market cap of 5.1B. Regarding current trading prices, CLEDUCATE.BO is priced at ₹46.47, while GLOBAL.NS trades at ₹105.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CLEDUCATE.BO currently has a P/E ratio of -11.25, whereas GLOBAL.NS's P/E ratio is 22.60. In terms of profitability, CLEDUCATE.BO's ROE is -0.10%, compared to GLOBAL.NS's ROE of +0.19%. Regarding short-term risk, CLEDUCATE.BO is less volatile compared to GLOBAL.NS. This indicates potentially lower risk in terms of short-term price fluctuations for CLEDUCATE.BO.Check GLOBAL.NS's competition here
CLEDUCATE.BO vs CLEDUCATE.NS Comparison May 2026
CLEDUCATE.BO plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CLEDUCATE.BO stands at 2.5B. In comparison, CLEDUCATE.NS has a market cap of 2.5B. Regarding current trading prices, CLEDUCATE.BO is priced at ₹46.47, while CLEDUCATE.NS trades at ₹47.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CLEDUCATE.BO currently has a P/E ratio of -11.25, whereas CLEDUCATE.NS's P/E ratio is -11.26. In terms of profitability, CLEDUCATE.BO's ROE is -0.10%, compared to CLEDUCATE.NS's ROE of -0.10%. Regarding short-term risk, CLEDUCATE.BO is less volatile compared to CLEDUCATE.NS. This indicates potentially lower risk in terms of short-term price fluctuations for CLEDUCATE.BO.Check CLEDUCATE.NS's competition here
CLEDUCATE.BO vs ZEELEARN.BO Comparison May 2026
CLEDUCATE.BO plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CLEDUCATE.BO stands at 2.5B. In comparison, ZEELEARN.BO has a market cap of 2B. Regarding current trading prices, CLEDUCATE.BO is priced at ₹46.47, while ZEELEARN.BO trades at ₹7.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CLEDUCATE.BO currently has a P/E ratio of -11.25, whereas ZEELEARN.BO's P/E ratio is 19.61. In terms of profitability, CLEDUCATE.BO's ROE is -0.10%, compared to ZEELEARN.BO's ROE of +0.19%. Regarding short-term risk, CLEDUCATE.BO is less volatile compared to ZEELEARN.BO. This indicates potentially lower risk in terms of short-term price fluctuations for CLEDUCATE.BO.Check ZEELEARN.BO's competition here
CLEDUCATE.BO vs ZEELEARN.NS Comparison May 2026
CLEDUCATE.BO plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CLEDUCATE.BO stands at 2.5B. In comparison, ZEELEARN.NS has a market cap of 2B. Regarding current trading prices, CLEDUCATE.BO is priced at ₹46.47, while ZEELEARN.NS trades at ₹7.14.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CLEDUCATE.BO currently has a P/E ratio of -11.25, whereas ZEELEARN.NS's P/E ratio is 19.61. In terms of profitability, CLEDUCATE.BO's ROE is -0.10%, compared to ZEELEARN.NS's ROE of +0.19%. Regarding short-term risk, CLEDUCATE.BO is less volatile compared to ZEELEARN.NS. This indicates potentially lower risk in terms of short-term price fluctuations for CLEDUCATE.BO.Check ZEELEARN.NS's competition here
CLEDUCATE.BO vs GOLDENCREST.BO Comparison May 2026
CLEDUCATE.BO plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CLEDUCATE.BO stands at 2.5B. In comparison, GOLDENCREST.BO has a market cap of 1.7B. Regarding current trading prices, CLEDUCATE.BO is priced at ₹46.47, while GOLDENCREST.BO trades at ₹331.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CLEDUCATE.BO currently has a P/E ratio of -11.25, whereas GOLDENCREST.BO's P/E ratio is 1951.76. In terms of profitability, CLEDUCATE.BO's ROE is -0.10%, compared to GOLDENCREST.BO's ROE of +0.01%. Regarding short-term risk, CLEDUCATE.BO is less volatile compared to GOLDENCREST.BO. This indicates potentially lower risk in terms of short-term price fluctuations for CLEDUCATE.BO.Check GOLDENCREST.BO's competition here
CLEDUCATE.BO vs COMPUSOFT.BO Comparison May 2026
CLEDUCATE.BO plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CLEDUCATE.BO stands at 2.5B. In comparison, COMPUSOFT.BO has a market cap of 1.1B. Regarding current trading prices, CLEDUCATE.BO is priced at ₹46.47, while COMPUSOFT.BO trades at ₹13.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CLEDUCATE.BO currently has a P/E ratio of -11.25, whereas COMPUSOFT.BO's P/E ratio is 39.21. In terms of profitability, CLEDUCATE.BO's ROE is -0.10%, compared to COMPUSOFT.BO's ROE of +0.02%. Regarding short-term risk, CLEDUCATE.BO is less volatile compared to COMPUSOFT.BO. This indicates potentially lower risk in terms of short-term price fluctuations for CLEDUCATE.BO.Check COMPUSOFT.BO's competition here
CLEDUCATE.BO vs COMPUSOFT.NS Comparison May 2026
CLEDUCATE.BO plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CLEDUCATE.BO stands at 2.5B. In comparison, COMPUSOFT.NS has a market cap of 1.1B. Regarding current trading prices, CLEDUCATE.BO is priced at ₹46.47, while COMPUSOFT.NS trades at ₹13.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CLEDUCATE.BO currently has a P/E ratio of -11.25, whereas COMPUSOFT.NS's P/E ratio is 39.12. In terms of profitability, CLEDUCATE.BO's ROE is -0.10%, compared to COMPUSOFT.NS's ROE of +0.02%. Regarding short-term risk, CLEDUCATE.BO is more volatile compared to COMPUSOFT.NS. This indicates potentially higher risk in terms of short-term price fluctuations for CLEDUCATE.BO.Check COMPUSOFT.NS's competition here
CLEDUCATE.BO vs KEERTI.NS Comparison May 2026
CLEDUCATE.BO plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CLEDUCATE.BO stands at 2.5B. In comparison, KEERTI.NS has a market cap of 733.1M. Regarding current trading prices, CLEDUCATE.BO is priced at ₹46.47, while KEERTI.NS trades at ₹71.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CLEDUCATE.BO currently has a P/E ratio of -11.25, whereas KEERTI.NS's P/E ratio is 55.35. In terms of profitability, CLEDUCATE.BO's ROE is -0.10%, compared to KEERTI.NS's ROE of +0.29%. Regarding short-term risk, CLEDUCATE.BO is more volatile compared to KEERTI.NS. This indicates potentially higher risk in terms of short-term price fluctuations for CLEDUCATE.BO.Check KEERTI.NS's competition here
CLEDUCATE.BO vs LCCINFOTEC.BO Comparison May 2026
CLEDUCATE.BO plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CLEDUCATE.BO stands at 2.5B. In comparison, LCCINFOTEC.BO has a market cap of 539.3M. Regarding current trading prices, CLEDUCATE.BO is priced at ₹46.47, while LCCINFOTEC.BO trades at ₹4.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CLEDUCATE.BO currently has a P/E ratio of -11.25, whereas LCCINFOTEC.BO's P/E ratio is -32.77. In terms of profitability, CLEDUCATE.BO's ROE is -0.10%, compared to LCCINFOTEC.BO's ROE of -1.66%. Regarding short-term risk, CLEDUCATE.BO is less volatile compared to LCCINFOTEC.BO. This indicates potentially lower risk in terms of short-term price fluctuations for CLEDUCATE.BO.Check LCCINFOTEC.BO's competition here
CLEDUCATE.BO vs LCCINFOTEC.NS Comparison May 2026
CLEDUCATE.BO plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CLEDUCATE.BO stands at 2.5B. In comparison, LCCINFOTEC.NS has a market cap of 536.8M. Regarding current trading prices, CLEDUCATE.BO is priced at ₹46.47, while LCCINFOTEC.NS trades at ₹4.19.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CLEDUCATE.BO currently has a P/E ratio of -11.25, whereas LCCINFOTEC.NS's P/E ratio is -47.11. In terms of profitability, CLEDUCATE.BO's ROE is -0.10%, compared to LCCINFOTEC.NS's ROE of -1.66%. Regarding short-term risk, CLEDUCATE.BO is less volatile compared to LCCINFOTEC.NS. This indicates potentially lower risk in terms of short-term price fluctuations for CLEDUCATE.BO.Check LCCINFOTEC.NS's competition here
CLEDUCATE.BO vs KEEPLEARN.BO Comparison May 2026
CLEDUCATE.BO plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CLEDUCATE.BO stands at 2.5B. In comparison, KEEPLEARN.BO has a market cap of 333.2M. Regarding current trading prices, CLEDUCATE.BO is priced at ₹46.47, while KEEPLEARN.BO trades at ₹2.12.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CLEDUCATE.BO currently has a P/E ratio of -11.25, whereas KEEPLEARN.BO's P/E ratio is -214.00. In terms of profitability, CLEDUCATE.BO's ROE is -0.10%, compared to KEEPLEARN.BO's ROE of -0.03%. Regarding short-term risk, CLEDUCATE.BO is less volatile compared to KEEPLEARN.BO. This indicates potentially lower risk in terms of short-term price fluctuations for CLEDUCATE.BO.Check KEEPLEARN.BO's competition here
CLEDUCATE.BO vs KEEPLEARN.NS Comparison May 2026
CLEDUCATE.BO plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CLEDUCATE.BO stands at 2.5B. In comparison, KEEPLEARN.NS has a market cap of 328.6M. Regarding current trading prices, CLEDUCATE.BO is priced at ₹46.47, while KEEPLEARN.NS trades at ₹2.11.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CLEDUCATE.BO currently has a P/E ratio of -11.25, whereas KEEPLEARN.NS's P/E ratio is -211.00. In terms of profitability, CLEDUCATE.BO's ROE is -0.10%, compared to KEEPLEARN.NS's ROE of -0.03%. Regarding short-term risk, CLEDUCATE.BO is less volatile compared to KEEPLEARN.NS. This indicates potentially lower risk in terms of short-term price fluctuations for CLEDUCATE.BO.Check KEEPLEARN.NS's competition here
CLEDUCATE.BO vs TREEHOUSE.NS Comparison May 2026
CLEDUCATE.BO plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CLEDUCATE.BO stands at 2.5B. In comparison, TREEHOUSE.NS has a market cap of 285.6M. Regarding current trading prices, CLEDUCATE.BO is priced at ₹46.47, while TREEHOUSE.NS trades at ₹6.78.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CLEDUCATE.BO currently has a P/E ratio of -11.25, whereas TREEHOUSE.NS's P/E ratio is -1.75. In terms of profitability, CLEDUCATE.BO's ROE is -0.10%, compared to TREEHOUSE.NS's ROE of -0.05%. Regarding short-term risk, CLEDUCATE.BO is less volatile compared to TREEHOUSE.NS. This indicates potentially lower risk in terms of short-term price fluctuations for CLEDUCATE.BO.Check TREEHOUSE.NS's competition here
CLEDUCATE.BO vs TREEHOUSE.BO Comparison May 2026
CLEDUCATE.BO plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CLEDUCATE.BO stands at 2.5B. In comparison, TREEHOUSE.BO has a market cap of 283.9M. Regarding current trading prices, CLEDUCATE.BO is priced at ₹46.47, while TREEHOUSE.BO trades at ₹6.88.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CLEDUCATE.BO currently has a P/E ratio of -11.25, whereas TREEHOUSE.BO's P/E ratio is -1.74. In terms of profitability, CLEDUCATE.BO's ROE is -0.10%, compared to TREEHOUSE.BO's ROE of -0.05%. Regarding short-term risk, CLEDUCATE.BO is less volatile compared to TREEHOUSE.BO. This indicates potentially lower risk in terms of short-term price fluctuations for CLEDUCATE.BO.Check TREEHOUSE.BO's competition here
CLEDUCATE.BO vs GTECJAINX.NS Comparison May 2026
CLEDUCATE.BO plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CLEDUCATE.BO stands at 2.5B. In comparison, GTECJAINX.NS has a market cap of 186.4M. Regarding current trading prices, CLEDUCATE.BO is priced at ₹46.47, while GTECJAINX.NS trades at ₹17.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CLEDUCATE.BO currently has a P/E ratio of -11.25, whereas GTECJAINX.NS's P/E ratio is -20.55. In terms of profitability, CLEDUCATE.BO's ROE is -0.10%, compared to GTECJAINX.NS's ROE of -2.61%. Regarding short-term risk, CLEDUCATE.BO is less volatile compared to GTECJAINX.NS. This indicates potentially lower risk in terms of short-term price fluctuations for CLEDUCATE.BO.Check GTECJAINX.NS's competition here
CLEDUCATE.BO vs UMESLTD.BO Comparison May 2026
CLEDUCATE.BO plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CLEDUCATE.BO stands at 2.5B. In comparison, UMESLTD.BO has a market cap of 143.2M. Regarding current trading prices, CLEDUCATE.BO is priced at ₹46.47, while UMESLTD.BO trades at ₹5.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CLEDUCATE.BO currently has a P/E ratio of -11.25, whereas UMESLTD.BO's P/E ratio is 41.69. In terms of profitability, CLEDUCATE.BO's ROE is -0.10%, compared to UMESLTD.BO's ROE of +0.02%. Regarding short-term risk, CLEDUCATE.BO is less volatile compared to UMESLTD.BO. This indicates potentially lower risk in terms of short-term price fluctuations for CLEDUCATE.BO.Check UMESLTD.BO's competition here
CLEDUCATE.BO vs UMESLTD.NS Comparison May 2026
CLEDUCATE.BO plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CLEDUCATE.BO stands at 2.5B. In comparison, UMESLTD.NS has a market cap of 140.3M. Regarding current trading prices, CLEDUCATE.BO is priced at ₹46.47, while UMESLTD.NS trades at ₹5.57.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CLEDUCATE.BO currently has a P/E ratio of -11.25, whereas UMESLTD.NS's P/E ratio is 40.85. In terms of profitability, CLEDUCATE.BO's ROE is -0.10%, compared to UMESLTD.NS's ROE of +0.02%. Regarding short-term risk, CLEDUCATE.BO is less volatile compared to UMESLTD.NS. This indicates potentially lower risk in terms of short-term price fluctuations for CLEDUCATE.BO.Check UMESLTD.NS's competition here
CLEDUCATE.BO vs EDUCOMP.BO Comparison May 2026
CLEDUCATE.BO plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CLEDUCATE.BO stands at 2.5B. In comparison, EDUCOMP.BO has a market cap of 121.2M. Regarding current trading prices, CLEDUCATE.BO is priced at ₹46.47, while EDUCOMP.BO trades at ₹0.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CLEDUCATE.BO currently has a P/E ratio of -11.25, whereas EDUCOMP.BO's P/E ratio is -0.34. In terms of profitability, CLEDUCATE.BO's ROE is -0.10%, compared to EDUCOMP.BO's ROE of +0.01%. Regarding short-term risk, CLEDUCATE.BO is less volatile compared to EDUCOMP.BO. This indicates potentially lower risk in terms of short-term price fluctuations for CLEDUCATE.BO.Check EDUCOMP.BO's competition here
CLEDUCATE.BO vs EDUCOMP.NS Comparison May 2026
CLEDUCATE.BO plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CLEDUCATE.BO stands at 2.5B. In comparison, EDUCOMP.NS has a market cap of 121.2M. Regarding current trading prices, CLEDUCATE.BO is priced at ₹46.47, while EDUCOMP.NS trades at ₹0.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CLEDUCATE.BO currently has a P/E ratio of -11.25, whereas EDUCOMP.NS's P/E ratio is -0.33. In terms of profitability, CLEDUCATE.BO's ROE is -0.10%, compared to EDUCOMP.NS's ROE of +0.01%. Regarding short-term risk, CLEDUCATE.BO is less volatile compared to EDUCOMP.NS. This indicates potentially lower risk in terms of short-term price fluctuations for CLEDUCATE.BO.Check EDUCOMP.NS's competition here
CLEDUCATE.BO vs MTEDUCARE.BO Comparison May 2026
CLEDUCATE.BO plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CLEDUCATE.BO stands at 2.5B. In comparison, MTEDUCARE.BO has a market cap of 117M. Regarding current trading prices, CLEDUCATE.BO is priced at ₹46.47, while MTEDUCARE.BO trades at ₹1.63.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CLEDUCATE.BO currently has a P/E ratio of -11.25, whereas MTEDUCARE.BO's P/E ratio is -0.60. In terms of profitability, CLEDUCATE.BO's ROE is -0.10%, compared to MTEDUCARE.BO's ROE of -9.24%. Regarding short-term risk, CLEDUCATE.BO is less volatile compared to MTEDUCARE.BO. This indicates potentially lower risk in terms of short-term price fluctuations for CLEDUCATE.BO.Check MTEDUCARE.BO's competition here
CLEDUCATE.BO vs MTEDUCARE.NS Comparison May 2026
CLEDUCATE.BO plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CLEDUCATE.BO stands at 2.5B. In comparison, MTEDUCARE.NS has a market cap of 115.6M. Regarding current trading prices, CLEDUCATE.BO is priced at ₹46.47, while MTEDUCARE.NS trades at ₹1.67.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CLEDUCATE.BO currently has a P/E ratio of -11.25, whereas MTEDUCARE.NS's P/E ratio is -0.60. In terms of profitability, CLEDUCATE.BO's ROE is -0.10%, compared to MTEDUCARE.NS's ROE of -9.24%. Regarding short-term risk, CLEDUCATE.BO is less volatile compared to MTEDUCARE.NS. This indicates potentially lower risk in terms of short-term price fluctuations for CLEDUCATE.BO.Check MTEDUCARE.NS's competition here
CLEDUCATE.BO vs DALALSTCOM.NS Comparison May 2026
CLEDUCATE.BO plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CLEDUCATE.BO stands at 2.5B. In comparison, DALALSTCOM.NS has a market cap of 0. Regarding current trading prices, CLEDUCATE.BO is priced at ₹46.47, while DALALSTCOM.NS trades at ₹1.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CLEDUCATE.BO currently has a P/E ratio of -11.25, whereas DALALSTCOM.NS's P/E ratio is -3.06. In terms of profitability, CLEDUCATE.BO's ROE is -0.10%, compared to DALALSTCOM.NS's ROE of +529.59%. Regarding short-term risk, CLEDUCATE.BO is more volatile compared to DALALSTCOM.NS. This indicates potentially higher risk in terms of short-term price fluctuations for CLEDUCATE.BO.Check DALALSTCOM.NS's competition here